Indeed, the anti-tumor activity of tipifarnib shown by Gilardi and colleagues in these HNSCC HRAS mutant models was equivalent to or exceeded that reported with a combination of MAPK and PI3K inhibitors in a HRAS mutant lung cancer model [47]. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.